<p>Neurogene Inc.（纳斯达克代码：NGNE - 获取免费报告）的股票被目前覆盖该股票的九家评级公司一致推荐为 “适度买入”，Marketbeat Ratings 报告称。一位股票研究分析师给予该股票卖出评级，两位给予持有评级，六位给予买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 46.1667 美元。</p>
<ul>
<li>Neurogene 股票暴跌 44%：这家生物科技公司还有希望吗？</li>
</ul>
<p>多家研究公司对 NGNE 进行了评论。Craig Hallum 于 6 月 17 日星期二开始对 Neurogene 的股票进行覆盖。他们对该股票设定了 “买入” 评级和 50.00 美元的目标价。Weiss Ratings 在周三的研究报告中重申了对 Neurogene 股票的 “卖出（d-）” 评级。最后，HC Wainwright 在周四的报告中重申了 “买入” 评级，并对 Neurogene 股票设定了 45.00 美元的目标价。</p>
<p><strong>阅读我们关于 NGNE 的最新研究报告</strong></p>
<h2>Neurogene 的机构交易</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Nuveen LLC 在第一季度购买了 Neurogene 股票的新股份，价值约 322,000 美元。Wellington Management Group LLP 在第一季度将其在 Neurogene 的持股增加了 58.5%。Wellington Management Group LLP 现在拥有 34,421 股该公司的股票，价值 403,000 美元，此前在上个季度又购买了 12,704 股。GAMMA Investing LLC 在第一季度将其在 Neurogene 的持股增加了 2,985.1%。GAMMA Investing LLC 现在拥有 4,134 股该公司的股票，价值 48,000 美元，此前在此期间又收购了 4,000 股。纽约梅隆银行在第一季度将其在 Neurogene 的持股增加了 8.2%。纽约梅隆银行现在拥有 24,445 股该公司的股票，价值 286,000 美元，此前在此期间又收购了 1,844 股。最后，EntryPoint Capital LLC 在第一季度收购了 Neurogene 的新股份，价值约 148,000 美元。目前 52.37% 的股票由机构投资者持有。</p>
<h2>Neurogene 股票下跌 4.3%</h2>
<p>周五，NGNE 股票开盘价为 30.21 美元。Neurogene 的 52 周低点为 6.88 美元，52 周高点为 74.49 美元。该公司的市值为 4.311 亿美元，市盈率为-7.01，贝塔值为 1.58。该公司的 50 日移动平均线为 20.09 美元，200 日移动平均线为 18.02 美元。</p>
<p>Neurogene（纳斯达克代码：NGNE - 获取免费报告）最近于 8 月 11 日星期一发布了季度财报。该公司报告季度每股收益为（1.05 美元），超出分析师一致预期的（1.15 美元）0.10 美元。平均而言，股票研究分析师预测 Neurogene 本年度每股收益为-4.27 美元。</p>
<h2>Neurogene 公司简介</h2>
<p>（获取免费报告）</p>
<p>Neurogene Inc 是一家生物技术公司，开发用于罕见神经疾病的基因治疗药物。该公司的产品候选包括 NGN-401，该药物包装在腺病毒 9 中，目前正在进行 Rett 综合症的 1/2 期临床试验；以及 NGN-101，一种常规基因治疗候选药物，目前正在进行 CLN5 Batten 病的 1/2 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Neurogene</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>3 只 heavily shorted 股票，可能在降息时上涨</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>博通获得第二个 420 美元目标价，CPO 胜利提升前景</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>百事可乐的深度折扣即将消失：趁现在买入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Neurogene 吗？</h2>
<p>在你考虑 Neurogene 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Neurogene 并不在名单上。</p>
<p>虽然 Neurogene 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NGNE

<p>Neurogene Inc.（纳斯达克代码：NGNE）获得了九位分析师的共识推荐评级为 “适度买入”。该股票有一项卖出评级、两项持有评级和六项买入评级，平均目标价格为 46.17 美元。最近的交易中，股价下跌了 4.3%，开盘价为 30.21 美元。公司报告的季度每股收益为（1.05 美元），超出预期。机构投资者持有该股票的 52.37%，其中 Nuveen 和 Wellington Management 等公司的持仓显著增加。Neurogene 专注于针对罕见神经疾病的基因治疗，正在进行其产品候选者的临床试验</p>

<p>Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $46.1667.</p>
<div class="lb-trans"><p>Neurogene Inc.（纳斯达克代码：NGNE - 获取免费报告）的股票被目前覆盖该股票的九家评级公司一致推荐为 “适度买入”，Marketbeat Ratings 报告称。一位股票研究分析师给予该股票卖出评级，两位给予持有评级，六位给予买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 46.1667 美元。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：这家生物科技公司还有希望吗？</li>
</ul>
</div><p>A number of research firms have commented on NGNE. Craig Hallum began coverage on shares of Neurogene in a research report on Tuesday, June 17th. They set a &#34;buy&#34; rating and a $50.00 price target on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Neurogene in a research report on Wednesday. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $45.00 target price on shares of Neurogene in a report on Thursday.</p>
<div class="lb-trans"><p>多家研究公司对 NGNE 进行了评论。Craig Hallum 于 6 月 17 日星期二开始对 Neurogene 的股票进行覆盖。他们对该股票设定了 “买入” 评级和 50.00 美元的目标价。Weiss Ratings 在周三的研究报告中重申了对 Neurogene 股票的 “卖出（d-）” 评级。最后，HC Wainwright 在周四的报告中重申了 “买入” 评级，并对 Neurogene 股票设定了 45.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Research Report on NGNE</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 NGNE 的最新研究报告</strong></p>
</div><h2>Institutional Trading of Neurogene</h2>
<div class="lb-trans"><h2>Neurogene 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Nuveen LLC bought a new stake in shares of Neurogene in the 1st quarter worth approximately $322,000. Wellington Management Group LLP raised its holdings in shares of Neurogene by 58.5% in the 1st quarter. Wellington Management Group LLP now owns 34,421 shares of the company's stock worth $403,000 after purchasing an additional 12,704 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Neurogene by 2,985.1% during the first quarter. GAMMA Investing LLC now owns 4,134 shares of the company's stock valued at $48,000 after acquiring an additional 4,000 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Neurogene by 8.2% during the first quarter. Bank of New York Mellon Corp now owns 24,445 shares of the company's stock valued at $286,000 after acquiring an additional 1,844 shares during the period. Finally, EntryPoint Capital LLC acquired a new stake in shares of Neurogene during the first quarter valued at approximately $148,000. 52.37% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Nuveen LLC 在第一季度购买了 Neurogene 股票的新股份，价值约 322,000 美元。Wellington Management Group LLP 在第一季度将其在 Neurogene 的持股增加了 58.5%。Wellington Management Group LLP 现在拥有 34,421 股该公司的股票，价值 403,000 美元，此前在上个季度又购买了 12,704 股。GAMMA Investing LLC 在第一季度将其在 Neurogene 的持股增加了 2,985.1%。GAMMA Investing LLC 现在拥有 4,134 股该公司的股票，价值 48,000 美元，此前在此期间又收购了 4,000 股。纽约梅隆银行在第一季度将其在 Neurogene 的持股增加了 8.2%。纽约梅隆银行现在拥有 24,445 股该公司的股票，价值 286,000 美元，此前在此期间又收购了 1,844 股。最后，EntryPoint Capital LLC 在第一季度收购了 Neurogene 的新股份，价值约 148,000 美元。目前 52.37% 的股票由机构投资者持有。</p>
</div><h2>Neurogene Trading Down 4.3%</h2>
<div class="lb-trans"><h2>Neurogene 股票下跌 4.3%</h2>
</div><p>NGNE stock opened at $30.21 on Friday. Neurogene has a 52 week low of $6.88 and a 52 week high of $74.49. The company has a market capitalization of $431.10 million, a price-to-earnings ratio of -7.01 and a beta of 1.58. The firm's 50-day moving average is $20.09 and its two-hundred day moving average is $18.02.</p>
<div class="lb-trans"><p>周五，NGNE 股票开盘价为 30.21 美元。Neurogene 的 52 周低点为 6.88 美元，52 周高点为 74.49 美元。该公司的市值为 4.311 亿美元，市盈率为-7.01，贝塔值为 1.58。该公司的 50 日移动平均线为 20.09 美元，200 日移动平均线为 18.02 美元。</p>
</div><p>Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.10. On average, equities research analysts predict that Neurogene will post -4.27 earnings per share for the current year.</p>
<div class="lb-trans"><p>Neurogene（纳斯达克代码：NGNE - 获取免费报告）最近于 8 月 11 日星期一发布了季度财报。该公司报告季度每股收益为（1.05 美元），超出分析师一致预期的（1.15 美元）0.10 美元。平均而言，股票研究分析师预测 Neurogene 本年度每股收益为-4.27 美元。</p>
</div><h2>Neurogene Company Profile</h2>
<div class="lb-trans"><h2>Neurogene 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.</p>
<div class="lb-trans"><p>Neurogene Inc 是一家生物技术公司，开发用于罕见神经疾病的基因治疗药物。该公司的产品候选包括 NGN-401，该药物包装在腺病毒 9 中，目前正在进行 Rett 综合症的 1/2 期临床试验；以及 NGN-101，一种常规基因治疗候选药物，目前正在进行 CLN5 Batten 病的 1/2 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Neurogene</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>3 Heavily Shorted Stocks That Could Pop on Rate Cuts</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Broadcom Gets Second $420 Target as CPO Win Boosts Outlook</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Neurogene</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>3 只 heavily shorted 股票，可能在降息时上涨</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>博通获得第二个 420 美元目标价，CPO 胜利提升前景</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>百事可乐的深度折扣即将消失：趁现在买入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NGNE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neurogene Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Neurogene 吗？</h2>
</div><p>Before you consider Neurogene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Neurogene 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Neurogene 并不在名单上。</p>
</div><p>While Neurogene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Neurogene 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Neurogene Inc.（NASDAQ:NGNE）被分析师平均推荐为 “适度买入”